Glycopyrronium
- Generic Name
- Glycopyrronium
- Brand Names
- Bevespi, Breztri, Cuvposa, Dartisla, Enurev Breezhaler, Glycate, Glyrx, Lonhala, Prevduo, Qbrexza, Robinul, Robinul Forte, Seebri Breezhaler, Sialanar, Tovanor Breezhaler, Ultibro
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28NO3
- CAS Number
- 740028-90-4
- Unique Ingredient Identifier
- A14FB57V1D
- Background
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications. Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of pept...
- Indication
Glycopyrronium formulated as a topical cloth is indicated to treat primary axillary hyperhidrosis in patients ≥9 years, and an inhalational solution is indicated for long term maintenance of airflow obstruction in COPD. A glycopyrronium intravenous and intramuscular injection is indicated in adults and pediatric patients to reduce the volume and acidity of g...
- Associated Conditions
- Airway Obstruction, Chronic Obstructive Pulmonary Disease (COPD), Increased upper airway secretion, Peptic Ulcer, Primary Axillary Hyperhidrosis, Sialorrhea, Cardiac vagal inhibitory reflexes, Cardiac vagal inhibitory reflexes caused by General Surgery, Cardiac vagal inhibitory reflexes caused by Medication, Gastric secretions, Peripheral muscarinic effects
- Associated Therapies
- -
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
- Conditions
- Interventions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1324
- Registration Number
- NCT01005901
- Locations
- 🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey
🇰🇷Novartis Investigative site, Seoul, Korea, Republic of
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1066
- Registration Number
- NCT00929110
- Locations
- 🇳🇿
Novartis Investigator Site, Wellington, New Zealand
🇺🇸Novartis Investigative site, Charlotte, North Carolina, United States
🇺🇸Novartis Investigative Center, Crescent Springs, Kentucky, United States
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 257
- Registration Number
- NCT00558285
- Locations
- 🇹🇷
Novartis Investigator Site, Izmir, Turkey
🇫🇷Novartis investigator site, Martigues, France
🇮🇹Novartis Investigator site, Modena, Italy
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 182
- Registration Number
- NCT00473694
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.